Mikocka-Walus, Antonina http://orcid.org/0000-0003-4864-3956
Skvarc, David
de Acosta, Manuel Barreiro
Evertsz, Floor Bennebroek
Bernstein, Charles N.
Burisch, Johan
Ferreira, Nuno
Gearry, Richard B.
Graff, Lesley A.
Jedel, Sharon
Mokrowiecka, Anna
Stengel, Andreas
Trindade, Inês A.
van Tilburg, Miranda A. L.
Knowles, Simon R.
Article History
Accepted: 23 August 2021
First Online: 7 September 2021
Declarations
:
: The authors have no conflicts of interest to declare that are relevant to the content of this article. Outside the present work, A. Mikocka-Walus served as an invited speaker at IBD-related conferences co-organized by Crohn's & Colitis Australia (a charity), Janssen and Ferring and received a speaker's fee. M. Barreiro-de Acosta has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma. Ch. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Janssen Canada, Roche Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Mylan Pharmaceuticals and Takeda; Educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker’s panel for Abbvie Canada, Janssen Canada, Takeda Canada, and Medtronic Canada. Received research funding from Abbvie Canada and Pfizer Canada. J. Burisch reports personal fees from AbbVie, personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants from Bristol Myers Squibb, grants from Novo Nordisk, outside the submitted work. L. Graff has served as a consultant for Roche Canada. R. Gearry has served on advisory boards for AbbVie New Zealand and Australia, Janssen New Zealand. Speaker’s panel for AbbVie New Zealand and Australia, Janssen New Zealand, Takeda Australia, Educational grants from AbbVie, New Zealand. A. Stengel has worked as consultant for a + r Berlin, Boehringer Ingelheim, Dr. Wilmar Schwabe, Microbiotica and Takeda. I. A. Trindade has received consultancy fees from Pfizer Inc. M van Tilburg has served as a consultant for Mahana Therapeutics, inc. S.R Knowles served as an invited speaker at IBD-related conferences co-organized by Crohn's & Colitis Australia (a charity) and Coeliac Australia (a charity), is a member of the Medical Advisory Committee for Glutagen Pty Ltd, and has received consultancy fees from AbbVie Pty Ltd and Janssen-Cilag Pty Ltd.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Swinburne University of Technology Human Research Ethics Committee on 25th May 2020 (Ref: 20202978–4430) as well as the local Human Research Ethics Committees of the participating collaborators, as required.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
Free to read: This content has been made available to all.